Trials / Completed
CompletedNCT00513877
Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
An Open Label Phase II Multicentre Clinical Trial of Single Agent Bortezomib in Patients With Malignant Pleural Mesothelioma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Cancer Trials Ireland · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of bortezomib and how well it works in treating patients with malignant pleural mesothelioma.
Detailed description
OBJECTIVES: Primary * Assess the clinical efficacy of bortezomib based on the evaluation of objective tumor response rate. Secondary * Assess additional clinical efficacy of bortezomib based on the evaluation of time to early disease progression and median overall 2-year survival rate. * Assess safety and toxicity in these patients. * Assess quality of life using the Lung Cancer Symptom Score. OUTLINE: This is a multicenter study. Patients are stratified according to current treatment (first-line vs second-line) Patients receive bortezomib IV on days 1, 8, 15, and 22. Treatment repeats every 5 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients exhibiting objective response or stable disease by week 20, may continue treatment at the discretion of the investigator until evidence of disease progression. Quality of life is assessed periodically. After completion of study treatment, patients are followed for up to 2 years. PROJECTED ACCRUAL: 57 first-line setting and 54 second-line setting patients will be accrued for this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bortezomib | |
| PROCEDURE | quality-of-life assessment |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2009-12-01
- First posted
- 2007-08-09
- Last updated
- 2014-12-31
Locations
13 sites across 4 countries: Belgium, Ireland, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT00513877. Inclusion in this directory is not an endorsement.